An agent-based model of Epstein-Barr virus transmission and vaccination
Year: 2026
Type: preprint
Abstract: Epstein- Barr virus (EBV) infects over 90\% of adults worldwide, causing infectious mononucleosis (IM) in adolescents and young adults and contributing to multiple malignancies. Despite its global burden, population- level transmission modeling of EBV remains limited. We present the first population- level agent-based model (ABM) of EBV transmission. The model is implemented with 10,000 agents and calibrated to age-specific seroprevalence data from the US National Health and Nutrition Examination Survey. Two complementary calibration methods are evaluated, each with its own distinct advantages: Approximate Bayesian Computation (ABC) and Bayesian Optimization with Expected Quantile Improvement (BO- EQI). ABC directly yields an approximate distribution of transmission parameters for propagation through vaccination scenarios. BO- EQI uses a limited simulation budget to identify well-fitting parameter vectors, particularly as the number of fitted parameters increases. We estimate parameter uncertainty at each resolution in a separate Gaussian-kernel posterior analysis, which requires additional simulations and an explicit model for discrepancies between simulated and observed prevalence. As an illustrative application, we simulate the population-level effect of hypothetical EBV vaccines over a 100-year projection horizon. Similar to a previous modeling study, our results suggest that vaccine durability is at least as critical as efficacy, and that a vaccine with direct protection against only EBV may persistently shift IM burden to older ages, an effect our longer simulation horizon reveals to be a durable equilibrium shift rather than a transient cohort phenomenon. These findings highlight the importance of careful vaccine target product profile design; in particular, our results suggest that dual efficacy against both EBV infection and IM progression represents the most promising achievable target profile, and should be a core design objective for next-generation EBV vaccines.
Source: medRxiv
Institutions: University of Guelph, University of British Columbia
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225909971
